Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (167)	12/9/1999 1:01:00 PM
From: Jim Oravetz	Respond to of 370

Vion Pharma Administers Tapet To First Phase I Patients NEW HAVEN, Conn. (Dow Jones)--Vion Pharmaceuticals Inc. (VION) said VNP20009, its first-generation Tapet bacterial vector, has been administered to the first patients enrolled into its Phase I intratumoral trial. Tapet are highly attenuated bacteria that have shown preferential replication in tumors compared to normal tissues in preclinical studies. Preferential replication lets the bacteria produce and deliver anticancer therapeutic products to tumors while minimizing toxicity to normal tissues. In a press release Wednesday, the biopharmaceutical company said the Phase I study, which is being conducted at the Cleveland Clinic Foundation, is designed to evaluate the safety, efficacy and optimum dose of an intratumoral administration for patients with either cutaneous or subcutaneous solid tumors. The company said the trial may involve up to 20 to 30 patients.

To: Jim Oravetz who wrote (167)	12/15/1999 8:43:00 PM
From: James Perry	Read Replies (1) \| Respond to of 370

Any information on the amount of royalty Boehringer Ingleheim will be obligated to pay on Promycin, if and when it is licensed? What relationship, if any, existed between Boehringer Ingleheim and Boehringer Mannheim? The latter company was acquired by Roche, and it is very memorable that Igen has been in court for the past two-three years, trying to collect the royalties that Mannheim agreed to pay them. I realize that a family of great wealth owns Boehringer, but I trust them about as far as I can throw a mule.